Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
JBJ-04-125-02 HCL is a novel, highly potent, mutant-specific, allosteric and orally bioavailable EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858R/T790M. JBJ-04-125-02 has the ability to block EGFRL858R/T790M/C797S signaling as well as the growth of cancer cells. There is anti-tumor activity in JBJ-04-125-02. It has the ability to suppress EGFRL858R/T790M/C797S signaling and cell proliferation both in vitro and in vivo when used alone.
Targets |
EGFR(L858R/T790M) (IC50 = 0.26 nM)
|
---|---|
ln Vitro |
JBJ-04-125-02, which has an IC50 of 0.26 nM for EGFRL858R/T790M, is a strong EGFR inhibitor with mutant structure and EGFR activity [1].
|
References |
[1]. To C, et al. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discov. 2019 Jul;9(7):926-943.
|
Molecular Formula |
C29H26FN5O3S
|
---|---|
Molecular Weight |
543.61184835434
|
Exact Mass |
543.17
|
Elemental Analysis |
C, 64.07; H, 4.82; F, 3.49; N, 12.88; O, 8.83; S, 5.90
|
CAS # |
2140807-05-0
|
Related CAS # |
JBJ-04-125-02;2060610-53-7
|
Appearance |
Solid powder
|
SMILES |
C1CN(CCN1)C2=CC=C(C=C2)C3=CC4=C(CN(C4=O)C(C5=C(C=CC(=C5)F)O)C(=O)NC6=NC=CS6)C=C3
|
InChi Key |
VHQVOTINPRYDAO-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C29H26FN5O3S/c30-21-5-8-25(36)24(16-21)26(27(37)33-29-32-11-14-39-29)35-17-20-2-1-19(15-23(20)28(35)38)18-3-6-22(7-4-18)34-12-9-31-10-13-34/h1-8,11,14-16,26,31,36H,9-10,12-13,17H2,(H,32,33,37)
|
Chemical Name |
2-(5-fluoro-2-hydroxyphenyl)-2-[3-oxo-5-(4-piperazin-1-ylphenyl)-1H-isoindol-2-yl]-N-(1,3-thiazol-2-yl)acetamide
|
Synonyms |
JBJ-04-125-02 racemate; JBJ0412502; JBJ-04-125-02; JBJ04-125-02; JBJ 0412502; JBJ 04-125-02; JBJ-0412502
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 100~250 mg/mL (184.0~459.9 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (3.83 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (3.83 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8396 mL | 9.1978 mL | 18.3955 mL | |
5 mM | 0.3679 mL | 1.8396 mL | 3.6791 mL | |
10 mM | 0.1840 mL | 0.9198 mL | 1.8396 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
JBJ-04-125-02 is effective in vitro and in vivo in EGFR C797S containing models. Cancer Discov . 2019 Jul;9(7):926-943. td> |
JBJ-04-125-02 inhibits EGFR and downstream signaling and tumor growth in H1975 cells in vitro and in vivo. Cancer Discov . 2019 Jul;9(7):926-943. td> |
JBJ-04-125-02 and osimertinib have distinct properties in H3255GR cells. Cancer Discov . 2019 Jul;9(7):926-943. td> |
Osimertinib can co-bind with JBJ-04-125-02 to mutant EGFR. Cancer Discov . 2019 Jul;9(7):926-943. td> |
The combination of JBJ-04-125-02 and osimertinib is more effective than either single agent alone. Cancer Discov . 2019 Jul;9(7):926-943. td> |